DOI: 10.36347/sjams.2019.v07i02.021

Pages: 535-538

Background. The potential benefits of thoracoscopic lobectomy for early stage non–small cell lung cancer have been well documented in the literature. However, little is known about the use of these techniques in patients requiring resection for infectious or inflammatory lung disease. The purpose of this study was to present our experience of VATS resection for infectious lung disease. Method: This is a retrospective review of prospectively collected data for 19 consecutive VATS lobectomy patients treated for infectious lung disease between January 2016 and December 2016. Results: 19 resections were performed; there were 12 female patients and 7 male patients. The average age was 52 years (range, 26 to 78 years).Indications for surgery included focal bronchiectasis (47.3%), pulmonary aspergillosis (26.3 %), cavitary disease (5.2%) and tuberculous destroyed lobe (21.05 %). The VATS lobectomy was converted to open thoracotomy in 1 patient. Blood transfusion for 2 patients after operative recovery. Thirty-day mortality was 7.14% (1 of14).video-assisted thoracoscopic lobectomy was associated with a shorter length of stay (5.0 days) and chest tube duration (4.0 days). Conclusions: Thoracoscopic lobectomy for individuals with infectious lung disease is a feasible procedure and can be accomplished safely with minimal morbidity and mortality. For experienced thoracoscopic surgeons, VATS lobectomy appears to be a sound option for lung-sparing, anatomic pulmonary resections.